Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT PRESENTATION OF THE 12-MONTH FOLLOW-UP RESULTS OF EU TRINITY OF THE LUX-VALVE PLUS CLINICAL STUDY AT PCR LONDON VALVES 2026

This announcement is made by Jenscare Scientific Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that recently, the 12-month clinical follow-up results of the global multi-center clinical trial of the LuX-Valve Plus transvenous tricuspid valve replacement system ("**EU TRINITY**") were released at the PCR London Valves 2026 (PCR London Valves 2026), demonstrating the excellent clinical performance and multi-size treatment advantages of the Company's product, which is expected to address a broad range of unmet clinical needs.

12-MONTH FOLLOW-UP RESULTS OF THE LUX-VALVE PLUS EU TRINITY STUDY

EU TRINITY is a prospective, multi-center, single-arm global clinical trial designed to evaluate the safety and efficacy of LuX-Valve Plus in patients with severe tricuspid regurgitation ("**TR**") who are at high surgical risk. The study involved 20 centers around the world, and the full analysis set ("**FAS**") for the 12-month follow-up results released herein included 149 patients, with 18 of the centers located in France, Germany, Spain, Denmark and the United Kingdom.

Patients with severe TR often have concomitant dilation of right ventricular and tricuspid annulus, which is one of the primary factors increasing the difficulty of TR intervention therapy. For large annulus patients, there are very few safe and effective clinical treatment options, indicating a significant unmet clinical needs. LuX-Valve Plus has seven valve sizes, accommodating annuli up to 70 mm with a minimum inner ring diameter of 30 mm. In the EU TRINITY study, over 75% of patients used valve sizes of 55 mm, 60 mm, 65 mm and 70 mm. The average age of these patients was 76.9 years and the average Tri-Score was as high as 12.6%; 12.1% of patients exhibited Severe TR, 51.0% exhibited Massive TR, and 36.9% exhibited Torrential TR.

The 12-month clinical follow-up results showed the excellent efficacy and safety of LuX-Valve Plus in the global patient population.

The clinical results showed:

(1) The device success rate was 96.6%; and

(2) The average device operation time was 41.6 ± 19.6 minutes.

The efficacy results showed:

(1) In terms of improvement in the TR grade, among the echocardiographically evaluable population at the 12-month follow-up (FAS, N=126), 80.6% of patients showed no more than moderate TR, with only 2.4% remaining severe TR and no cases of massive or greater TR;

(2) In terms of New York Heart Association cardiac function improvement, 92.1% of patients in the evaluable population at the 12-month follow-up (FAS, N=127) achieved postoperative cardiac function class I/II; and

(3) In terms of quality of life improvement, the Kansas City Cardiomyopathy Questionnaire scores of paired patients in the FAS improved by approximately 17 points on average; in addition, the 6-minute walking distance for paired patients in the FAS improved by approximately 39 meters on average.

The safety results showed:

12-Month Composite Events Adjudicated by the Clinical Events Committee (CEC)	**FAS (N=149)**
Cardiovascular mortality	6.0% (9 cases)
Myocardial infarction	0
Strokes	2.0% (3 cases)
New-onset renal failure	1.3% (2 cases)
Severe bleeding (including fatal, life-threatening and extensive bleeding as defined by MVARC)	6.7% (10 cases)
Non-selective tricuspid valve surgery/intervention post procedure	4.0% (6 cases)
Major cardiac structural complications	2.7% (4 cases)
Major access site and vascular complications	0
Device-related pulmonary embolism	0
New pacemaker implantation due to AV block	8.7% (13 cases)
Composite events rate	24.8%

Despite the advanced age, high surgical risk, severe TR and significant annular dilation of the enrolled patients, the 12-month clinical follow-up results of the EU TRINITY study demonstrated that LuX-Valve Plus continued to exhibit sustained and excellent safety and long-term stable procedural performance in the global patient population. Significant reduction was observed in TR grade, accompanied by continued improvement in patients' quality of life and a low incidence of composite adverse events.

As of the date of this announcement, over 1,200 implantation cases have been completed worldwide for the LuX-Valve Plus transcatheter tricuspid valve replacement system independently developed by the Company, and the longest follow-up record was over seven years. The product has obtained EU MDR CE certification. It has also received the US FDA's approval on the Pivotal IDE trial, with orderly patient enrollment, and has obtained the CMS approval of the Category B Medicare Coverage, with both the standard-of-care and the investigational device being covered and being reimbursed. The 12-month follow-up results of the EU TRINITY study further strengthened the evidence-based medical foundation for the long-term clinical application of the LuX-Valve Plus transcatheter tricuspid valve replacement system. Leveraging long-term, robust clinical research and therapeutic evidence, the product continues to establish a deep and comprehensive evidence-based medical advantage.

The Company's commercialized products across the tricuspid, mitral and aortic valve lines have successively gained high recognition from experts and physicians worldwide. Leveraging sustained original technological innovation, a diversified product matrix and global clinical accumulation, the Company will accelerate the global commercialization of its multi-valve product portfolio and continue to provide innovative treatment options for patients with structural heart disease.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, November 22, 2026

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.